EAM
APGE

Eventide Asset Management’s Apogee Therapeutics APGE Stock Holding History

Eventide Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.5M Sell
260,000
-297,423
-53% -$26.8M 0.46% 72
2026
Q1 		$46.9M Buy
557,423
+121,408
+28% +$8.82M 0.78% 43
2025
Q4 		$32.9M Buy
+436,015
New +$27.5M 0.51% 68

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Eventide Asset Management's APGE Position: Q2 2026 in Review

Eventide Asset Management reduced its Apogee Therapeutics (APGE) stake by 53% in Q2 2026, selling an estimated $26.8M and leaving 260,000 shares worth $34.5M. The position accounts for 0.46% of the portfolio, ranked #72.

Eventide Asset Management first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. The position peaked at $46.9M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Eventide Asset Management held 260,000 shares of Apogee Therapeutics worth $34.5M as of Q2 2026.
  • Eventide Asset Management sold 297,423 Apogee Therapeutics shares in Q2 2026, an estimated $26.8M.
  • Apogee Therapeutics made up 0.46% of Eventide Asset Management's portfolio in Q2 2026, its #72 holding.
  • Eventide Asset Management first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Eventide Asset Management's Apogee Therapeutics position peaked at $46.9M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.